CoCensys has hands full

CoCensys Inc. faces the task of reviving its fortunes with a slender cushion of cash following the recent reorganization of its management and partnerships, including the announcement last week that one of two marketed drugs will be dropped and that its top executive R&D position would be eliminated.

The company's immediate priorities involve finding more products for its underutilized sales force, funding clinical trials of its lead compound, and finding partners for its earlier-stage products.